Health & Environmental Research Online (HERO)


Print Feedback Export to File
446489 
Journal Article 
Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease 
Abreu, MT; Geller, JL; Vasiliauskas, EA; Kam, LY; Vora, P; Martyak, LA; Yang, HY; Hu, B; Lin, YC; Keenan, G; Price, J; Landers, CJ; Adams, JS; Targan, SR 
2006 
Yes 
Journal of Clinical Gastroenterology
ISSN: 0192-0790
EISSN: 1539-2031 
40 
1 
55-63 
English 
Objective: osteoporosis is a common complication of Crohn's disease (CD). Glucocorticoid use and detrimental effects of inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha) can lead to osteoporosis. The aim of this study was to assess the ability of treatment with the TNF-alpha antagonist infliximab to increase bone formation as measured by surrogate markers of bone turnover in patients with active CD. Methods: Sera from 38 prospectively enrolled CD patients were examined for levels of bone alkaline phosphatase (BAP), N-tclopeptide of type I collagen (NTX), immumoreactive parathyroid hormone (iPTH), calcium, and pro-inflammatory cytokines at baseline and 4 weeks following infliximab infusion. Crohn's Disease Activity Index (CDAI), Inflammatory Bowel Disease Questionnaire (IBDQ), and glucocorticoid dose also were collected. Results: In this cohort, CDAI and IBDQ scores were significantly improved at week 4 (P < 0.001). Infliximab therapy was associated with an increase in BAP, a marker of bone formation (P = 0.010), whereas NTX, a marker of bone resorption, was not increased (P = 0.801). Among 22 patients who were taking glucocorticoids, mean glucocorticoid dose decreased 36% (P < 0.001; -7.9 mg). Conclusions: Treatment with infliximab was associated with increased markers of bone fort-nation (BAP) without increasing bone resorption (NTX). This effect may be due to a beneficial effect of TNF-alpha blockade on bone turnover, a beneficial effect on CD activity resulting in decreased glucocorticoid dose, or both. Studies of longer duration are needed to assess the effect of infliximab on bone mineral density. 
Crohn's disease; osteoporosis; osteopenia; infliximab; turner necrosis; factor-alpha; osteoblast; osteoclast; inflammatory-bowel-disease; necrosis-factor-alpha; ulcerative-colitis; tnf-alpha; osteoblast differentiation; hemodialysis-patients; induced; osteoporosis; mineral density; fracture risk; dowel disease